Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2022-08-25 Purchase |
2022-08-25 7:37 pm |
Aeglea BioTherapeutics Inc. | AGLE | Souza Marcio Director |
90,000 | $0.5608 | $50,472 | 90,000 (Direct) |
View |
| 2022-06-08 Purchase |
2022-06-10 6:24 pm |
Aeglea BioTherapeutics Inc. | AGLE | Hanley Jr. Michael Conick Chief Commercial Officer |
28,200 | $0.71 | $20,022 | 36,200 (Direct) |
View |
| 2022-03-16 Purchase |
2022-03-18 06:46 am |
Aeglea BioTherapeutics Inc. | AGLE | Quinn Anthony G. President & CEO |
80,079 | $2.344 | $187,705 | 816,835 (Indirect Direct) |
View |
| 2022-03-11 Purchase |
2022-03-15 6:32 pm |
Aeglea BioTherapeutics Inc. | AGLE | Quinn Anthony G. President & CEO |
144,666 | $1.942 | $280,943 | 739,756 (Indirect Direct) |
View |
| 2022-03-11 Purchase |
2022-03-15 6:30 pm |
Aeglea BioTherapeutics Inc. | AGLE | Alspaugh Jonathan Chief Financial Officer |
75,000 | $2.08 | $156,000 | 165,372 (Direct) |
View |
| 2021-12-09 Purchase |
2021-12-13 8:41 pm |
Aeglea BioTherapeutics Inc. | AGLE | Shanafelt Armen Director |
150,000 | $3.6646 | $549,692 | 150,000 (Direct) |
View |
| 2021-12-09 Purchase |
2021-12-13 8:39 pm |
Aeglea BioTherapeutics Inc. | AGLE | Quinn Anthony G. President & CEO |
53,634 | $3.7098 | $198,972 | 595,090 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
Ownership |
2023-06-30 5:13 pm |
N/A 2033-06-22 |
Aeglea BioTherapeutics Inc. | AGLE | HENDERSON MICHAEL THOMAS Director |
0 | $0 | 1,950,000 (Direct) |
View |
| 2023-06-22 Option Award |
2023-06-30 4:34 pm |
N/A 2033-06-22 |
Aeglea BioTherapeutics Inc. | AGLE | Alspaugh Jonathan President and CFO |
19,787,969 | $0 | 19,787,969 (Direct) |
View |
| 2023-06-22 Option Award |
2023-06-30 4:33 pm |
N/A 2033-06-22 |
Aeglea BioTherapeutics Inc. | AGLE | Cox Russell J. Director |
1,950,000 | $0 | 1,950,000 (Direct) |
View |
| 2023-06-22 Option Award |
2023-06-30 4:32 pm |
N/A 2033-06-22 |
Aeglea BioTherapeutics Inc. | AGLE | Magovcevic-Liebisch Ivana Director |
1,950,000 | $0 | 1,950,000 (Direct) |
View |
| 2023-06-22 Option Award |
2023-06-30 4:31 pm |
N/A 2033-06-22 |
Aeglea BioTherapeutics Inc. | AGLE | Smith Hunter C Director |
1,950,000 | $0 | 1,950,000 (Direct) |
View |
| 2023-06-22 Option Award |
2023-06-30 4:30 pm |
N/A 2033-06-22 |
Aeglea BioTherapeutics Inc. | AGLE | Lawton Alison Frances Director |
1,950,000 | $0 | 1,950,000 (Direct) |
View |
| 2023-02-23 Option Award |
2023-02-24 6:25 pm |
N/A 2033-02-22 |
Aeglea BioTherapeutics Inc. | AGLE | Neuman Linda L Chief Medical Officer |
550,000 | $0 | 550,000 (Direct) |
View |
| 2023-02-23 Option Award |
2023-02-24 6:24 pm |
N/A 2033-02-22 |
Aeglea BioTherapeutics Inc. | AGLE | Kastenmayer James Paul General Counsel |
500,000 | $0 | 500,000 (Direct) |
View |
| 2023-02-23 Option Award |
2023-02-24 6:22 pm |
N/A 2033-02-22 |
Aeglea BioTherapeutics Inc. | AGLE | Hanley Jr. Michael Conick Chief Business Officer |
500,000 | $0 | 500,000 (Direct) |
View |
| 2023-02-23 Option Award |
2023-02-24 6:20 pm |
N/A 2033-02-22 |
Aeglea BioTherapeutics Inc. | AGLE | Alspaugh Jonathan Chief Financial Officer |
640,000 | $0 | 640,000 (Direct) |
View |
| 2022-11-14 Option Award |
2023-01-27 6:20 pm |
N/A 2032-11-13 |
Aeglea BioTherapeutics Inc. | AGLE | Neuman Linda L Chief Medical Officer |
25,000 | $0 | 25,000 (Direct) |
View |
Ownership |
2023-01-27 6:18 pm |
N/A N/A |
Aeglea BioTherapeutics Inc. | AGLE | Neuman Linda L Chief Medical Officer |
0 | $0 | 140,250 (Direct) |
View |
| 2022-11-29 Option Award |
2022-12-01 8:47 pm |
N/A 2032-11-28 |
Aeglea BioTherapeutics Inc. | AGLE | Goldberg Jeff Marc President and CEO |
1,884,838 | $0 | 1,884,838 (Direct) |
View |
| 2022-08-23 Option Award |
2022-08-25 7:39 pm |
N/A 2032-08-22 |
Aeglea BioTherapeutics Inc. | AGLE | Kastenmayer James Paul Interim CEO & General Counsel |
130,000 | $0 | 130,000 (Direct) |
View |
Ownership |
2022-08-25 7:37 pm |
N/A N/A |
Aeglea BioTherapeutics Inc. | AGLE | Kastenmayer James Paul Interim CEO & General Counsel |
0 | $0 | 219,000 (Direct) |
View |
| 2022-08-23 Option Award |
2022-08-25 7:36 pm |
N/A 2032-08-22 |
Aeglea BioTherapeutics Inc. | AGLE | Sloan Leslie Chief Operating Officer |
130,000 | $0 | 130,000 (Direct) |
View |
| 2022-08-23 Option Award |
2022-08-25 7:35 pm |
N/A 2032-08-22 |
Aeglea BioTherapeutics Inc. | AGLE | Hanley Jr. Michael Conick Chief Business Officer |
130,000 | $0 | 130,000 (Direct) |
View |
| 2022-08-23 Option Award |
2022-08-25 7:34 pm |
N/A 2032-08-22 |
Aeglea BioTherapeutics Inc. | AGLE | Alspaugh Jonathan Chief Financial Officer |
130,000 | $0 | 130,000 (Direct) |
View |
| 2022-06-07 Option Award |
2022-06-10 06:04 am |
N/A 2032-06-06 |
Aeglea BioTherapeutics Inc. | AGLE | Lawton Alison Frances Director |
43,000 | $0 | 43,000 (Direct) |
View |
| 2022-06-07 Option Award |
2022-06-09 9:22 pm |
N/A 2032-06-06 |
Aeglea BioTherapeutics Inc. | AGLE | Shanafelt Armen Director |
43,000 | $0 | 43,000 (Direct) |
View |
| 2022-06-07 Option Award |
2022-06-09 9:21 pm |
N/A 2032-06-06 |
Aeglea BioTherapeutics Inc. | AGLE | Souza Marcio Director |
43,000 | $0 | 43,000 (Direct) |
View |
| 2022-06-07 Option Award |
2022-06-09 9:19 pm |
N/A 2032-06-06 |
Aeglea BioTherapeutics Inc. | AGLE | Smith Hunter C Director |
43,000 | $0 | 43,000 (Direct) |
View |
| 2022-06-07 Option Award |
2022-06-09 9:18 pm |
N/A 2032-06-06 |
Aeglea BioTherapeutics Inc. | AGLE | Mahatme Sandesh Director |
43,000 | $0 | 43,000 (Direct) |
View |
| 2022-06-07 Option Award |
2022-06-09 9:17 pm |
N/A 2032-06-06 |
Aeglea BioTherapeutics Inc. | AGLE | Magovcevic-Liebisch Ivana Director |
43,000 | $0 | 43,000 (Direct) |
View |
| 2022-06-07 Option Award |
2022-06-09 9:15 pm |
N/A 2032-06-06 |
Aeglea BioTherapeutics Inc. | AGLE | LAWLIS V BRYAN Director |
43,000 | $0 | 43,000 (Direct) |
View |
| 2022-06-07 Option Award |
2022-06-09 9:13 pm |
N/A 2032-06-06 |
Aeglea BioTherapeutics Inc. | AGLE | Cox Russell J. Director |
43,000 | $0 | 43,000 (Direct) |
View |
| 2022-02-17 Option Award |
2022-02-22 4:57 pm |
N/A 2032-02-16 |
Aeglea BioTherapeutics Inc. | AGLE | Quinn Anthony G. President & CEO |
350,000 | $0 | 350,000 (Direct) |
View |
| 2022-02-17 Option Award |
2022-02-22 4:55 pm |
N/A 2032-02-16 |
Aeglea BioTherapeutics Inc. | AGLE | Weber Steven VP, Controller&Princ Acctg Off |
30,000 | $0 | 30,000 (Direct) |
View |
| 2022-02-17 Option Award |
2022-02-22 4:54 pm |
N/A 2032-02-16 |
Aeglea BioTherapeutics Inc. | AGLE | Sloan Leslie Chief Operating Officer |
180,000 | $0 | 180,000 (Direct) |
View |
| 2022-02-17 Option Award |
2022-02-22 4:51 pm |
N/A 2032-02-16 |
Aeglea BioTherapeutics Inc. | AGLE | Hanley Jr. Michael Conick Chief Commercial Officer |
160,000 | $0 | 160,000 (Direct) |
View |
| 2022-02-17 Option Award |
2022-02-22 4:50 pm |
N/A 2032-02-16 |
Aeglea BioTherapeutics Inc. | AGLE | Alspaugh Jonathan Chief Financial Officer |
170,000 | $0 | 170,000 (Direct) |
View |
| 2018-12-28 Ownership |
2022-02-14 5:19 pm |
N/A N/A |
Aeglea BioTherapeutics Inc. | AGLE | Quinn Anthony G. President & CEO |
266,295 | $0 | 537,640 (Direct) |
View |